Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

Core Insights - Ocular Therapeutix, Inc. is focused on developing and commercializing innovative therapies for retinal diseases and other eye conditions [3] - The company will host a conference call and webcast on August 7, 2024, to discuss its recent business progress and financial results for Q2 2024 [1][5] Company Overview - Ocular Therapeutix is a biopharmaceutical company dedicated to improving vision through innovative therapies [3] - The company’s product candidate AXPAXLI™ is currently in Phase 3 clinical trials for wet age-related macular degeneration [3] - Ocular's pipeline includes DEXTENZA®, an FDA-approved corticosteroid for ocular inflammation and pain, and PAXTRAVA™, which has completed a Phase 2 clinical trial for open-angle glaucoma [6]